MHE October 2025
Site neutrality payment, innovations in care delivery and value-based pricing of drugs could at least help to moderate the huge growth in expenditures.
Novo Nordisk has a factor VIII mimetic in a phase 3 trial, and a Chinese company is forging ahead with its gene therapy product.
At first, it was tentative. But now almost all parts of the U.S. healthcare system are racing to adopt some form of artificial intelligence. Some leaders caution about using it too widely, too fast.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
3 insights from the third set of drugs for Medicare price negotiations
3
Higher use, not higher prices, drove a 50% spike in urgent care spending
4
Medicaid expansion associated with lower overall breast cancer mortality
5